EP1299362A1 - Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci - Google Patents

Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci

Info

Publication number
EP1299362A1
EP1299362A1 EP01952440A EP01952440A EP1299362A1 EP 1299362 A1 EP1299362 A1 EP 1299362A1 EP 01952440 A EP01952440 A EP 01952440A EP 01952440 A EP01952440 A EP 01952440A EP 1299362 A1 EP1299362 A1 EP 1299362A1
Authority
EP
European Patent Office
Prior art keywords
branched
straight chained
compound
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01952440A
Other languages
German (de)
English (en)
Other versions
EP1299362A4 (fr
Inventor
Bharat Lagu
John Wetzel
Mohammad R. Marzabadi
John E. Deleon
Charles Gluchowski
Stewart Noble
Dhanapalan Nagarathnam
George Chiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Synaptic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharmaceutical Corp filed Critical Synaptic Pharmaceutical Corp
Publication of EP1299362A1 publication Critical patent/EP1299362A1/fr
Publication of EP1299362A4 publication Critical patent/EP1299362A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • MCH Melanin-concentrating hormone
  • MCH has been reported to participate in a variety of processes including feeding, water balance, energy metabolism, general arousal/attention state, memory and cognitive functions, and psychiatric disorders (for reviews, see Baker, 1991; Baker, 1994; Nahon, 1994; Knigge et al., 1996) . Its role in feeding or body weight regulation is supported by a recent Nature publication (Qu et al., 1996) demonstrating that MCH is overexpressed in the hypothalamus of ob/ob mice compared with o /+ mice, and that fasting further increased MCH mRNA in both obese and normal mice during fasting. MCH also stimulated feeding in normal rats when injected into the lateral ventricles
  • MCH mRNA levels
  • the ligand retained biological activity and exhibited specific binding to a variety of cell lines including mouse melanoma (B16-F1, G4F, and G4F-7), PC12, and COS cells.
  • mouse melanoma B16-F1, G4F, and G4F-7
  • PC12 PC12
  • COS cells C12 cells
  • the K D O.ll ⁇ nM
  • MCH methylcellulose
  • lateral hypothalamus a brain area implicated in the regulation of thirst and hunger
  • orexins A and B which are potent orexigenic agents, have been shown to have very similar localization to MCH in the lateral hypothalamus (Sakurai et al . , 1998).
  • MCH mRNA levels in this brain region are increased in rats after 24 hours of food-deprivation (Herve and Fellman, 1997); after insulin injection, a significant increase in the abundance and staining intensity of MCH immunoreactive perikarya and fibres was observed concurrent with a significant increase in the level of MCH mRNA (Ba jaoui-Bouhaddi et al . , 1994) . Consistent with the ability of MCH to stimulate feeding in rats (Rossi et al . , 1997) is the observation that MCH mRNA levels are upregulated in the hypothalami of obese ob/ob mice (Qu et al .
  • MCH appears to act as a functional antagonist of the melanocortin system in its effects on food intake and on hormone secretion within the HPA (hypothalamopituitary/adrenal axis) (Ludwig et al . , 1998) .
  • the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subthalamus where they lie and may be a part of some of the so-called "extrapyramidal" motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers (Bittencourt et al . , 1992) . In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Clinically it may be of some value 'to consider the involvement of this MCH system in movement disorders, such as Parkinson' s disease and Huntingdon' s Chorea in which extrapyramidal circuits are known to be involved.
  • MCH may regulate reproductive functions in male and female rats .
  • MCH transcripts and MCH peptide were found within germ cells in testes of adult rats, suggesting that MCH may participate in stem cell renewal and/or differentiation of early spermatocytes (Hervieu et al . , 1996).
  • MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (VMN) stimulated sexual activity in female rats (Gonzalez et al . , 1996) .
  • MCH stimulated luteinizing hormone
  • anti-MCH antiserum inhibited LH release
  • the zona incerta which contains a large population of MCH cell bodies, has previously been identified as a regulatory site for the pre-ovulatory LH surge (MacKenzie et al . , 1984).
  • MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin.
  • MCH analogues may also be useful in treating epilepsy.
  • MCH has also been observed to affect behavioral correlates of cognitive functions .
  • MCH treatment hastened extinction of the passive avoidance response in rats (McBride et al . , 1994), raising the possibility that MCH receptor antagonists may be beneficial for memory storage and/or retention.
  • a possible role for MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers.
  • MCH may participate in the regulation of fluid intake. ICV infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume (Parkes, 1996) . Together with anatomical data reporting the presence of MCH in fluid regulatory areas of the brain, the results indicate that MCH may be an important peptide involved in the central control of fluid homeostasis in mammals .
  • the term "antagonist” refers to a compound which binds to, and decreases the activity of, a receptor in the presence of an agonist.
  • activation may be measured using any appropriate second messenger system which is coupled to the receptor in a cell or tissue in which the receptor is expressed.
  • second messenger systems are adenylate cyclase, intracellular calcium mobilization, ion channel activation, guanylate cyclase and inositol phospholipid hydrolysis.
  • agonist refers to a compound which binds to, and increases activity of, a receptor as compared with the activity of the receptor in the absence of any agonist.
  • the synthesis of novel compounds which bind selectively to the cloned human melanin-concentrating hormone-1 (MCHl) receptor, compared to other cloned G-protein coupled receptors, and inhibit the activation of the cloned receptors as measured in in vi tro assays is disclosed.
  • MCHl melanin-concentrating hormone-1
  • the compounds of the present invention may also be used to treat abnormal conditions such as feeding disorders (obesity, bulimia and bulimia nervosa) , sexual/reproductive disorders, depression, anxiety, depression and anxiety, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, sleep disturbances, or any condition in which antagonism of an MCHl receptor may be beneficial.
  • feeding disorders ovalbumina, bulimia and bulimia nervosa
  • sexual/reproductive disorders depression, anxiety, depression and anxiety
  • epileptic seizure hypertension
  • cerebral hemorrhage congestive heart failure
  • sleep disturbances or any condition in which antagonism of an MCHl receptor may be beneficial.
  • the compounds of the present invention may be used to reduce the body mass of a subject.
  • This invention provides a compound having the structure
  • each of Y ⁇ , Y 2 , Y 3 , Y 4 and Y 5 is independently -H; straight chained or branched C ⁇ C- ? alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 3 , -OCOR 3 , -COR 3 , -CON(R 3 ) 2 , or -COOR 3 ; or any two of Y ⁇ / Y 2 , Y 3 , Y 4 and Y 5 present on adjacent carbon atoms can constitute a ethylenedioxy group;
  • each X is independently S; 0; or NR 3 ; wherein R x is -H; -N0 2 ; -CN; straight chained or branched C- L -C- 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; or -C0 2 (CH 2 ) n V;
  • R 2 is -H; straight • chained or branched C 1 -C 7 alkyl, hydroxyalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C 3 -C 10 cycloalkyl-C 1 -C 10 -alkyl, C 3 -C 10 cycloalkyl-C 1 -C 10 -monofluoroalkyl or C 3 -C 10 cycloalkyl-C ⁇ - C i0 -polyfluoroalkyl; -CN; -CH 2 XR 3 , -CH 2 X (CH 2 ) p NHR 3 , -(CH 2 ) n NHR 3
  • each R 3 is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 4 is (i)
  • dashed line represents a single bond or a double bond
  • each R is independently -H; -F; straight chained or branched C x ⁇ C- ⁇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -OR 3 ; or -CON(R 3 ) 2 ;
  • each V is independently aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; wherein each R 5 is -H; -N0 2 ; -N 3 ;
  • R 6 is -H; straight chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ;
  • -CON(R 3 ) 2 aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -0R 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C ] _-C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 7 is H; F; CI; Br; I; -N0 2 ; -N 3 ; -CN; straight chained or branched C ] _-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -C0R 3 ; -C0 2 R 3 ; or -C0N ( R 3 ) 2 ;
  • R 8 is independently straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • Z is naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, phthalazinyl, quinoxalinyl, indolyl, benzo [b] furanyl, or benzo [b] thiophenyl; wherein the naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, phthalazinyl, quinoxalinyl, indolyl, benzo [b] furanyl, or benzo [b] thiophenyl may be substituted with one or more F; CI; Br; I; C0R 3 ; C0 2 R 3 ; -C0N(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -0R 3 ; -SR 3 ; (CH 2 ) g OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C
  • each m is independently an integer from 0 to 3 inclusive;
  • n is independently an integer from 0 to 5 inclusive;
  • each p is independently an integer from 1 to 7 inclusive;
  • q is an integer from 1 to 3 inclusive
  • r is an integer from 0 to 3 inclusive; wherein t is an integer from 2 to 6 inclusive;
  • This invention further provides a compound having the structure :
  • each R is independently -H; -F; straight chained or branched C x -C ⁇ j alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -SR 3 ; -C0 2 R 3 ; or
  • each R x is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -(CH 2 ) 0R 3 ; -C0R 3 ; -C0 2 R 3 ; or -C0N(R 3 ) 2 ;
  • each R 2 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C -C ⁇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -C0R 3 ; -C0 2 R 3 ; or -C0N(R 3 ) 2 ; or aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 )
  • each R 3 is independently -H; straight chained or branched C; ⁇ _-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • M is aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; C0R 3 ; C0 2 R 3 ; -C0N(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; ⁇ SR 3 ; (CH 2 ) q 0R 3 ; (CH 2 ) q SR 3 ; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • X is (CH 2 ) n , 0, S or NR 3 ;
  • aryl or heteroaryl optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -0R 3 ; -SR 3 ; (CH 2 ) q 0R 3 ; (CH 2 ) q SR 3 ; straight chained or branched C ⁇ C- ; alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C alkynyl; C 3 -C 7 cycloalkyl;
  • m is an integer from 0 to 4 inclusive;
  • n is an integer from 0 to 6 inclusive
  • p is an integer from 1 to 4 inclusive
  • q is an integer from 1 to 3 inclusive
  • This invention also provides a compound having the structure :
  • each R is independently -H; -F; straight chained or branched C ⁇ C- ? alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -0R 3 ; or -C0N(R 3 ) 2 ;
  • each R x is independently -H; F; Cl; Br; I; -N0 2 ; -N 3 ; -CN; straight chained or branched C ⁇ C- alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p 0R 3 ; -C0R 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ;
  • C 1 -C 7 alkyl monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • each R 3 is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 5 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -C0R 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ;
  • V is H; aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C ⁇ C-y alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • aryl or heteroaryl optionally substituted with one or more F; CI ; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C ⁇ -C ⁇ alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl;
  • each m is independently an integer from 0 to 3 inclusive;
  • n is an integer from 0 to 2 inclusive;
  • t is an integer from 2 to 6 inclusive
  • each of Y ⁇ r Y 2 , Y 3 , Y and Y 5 is independently -H; straight chained or branched C ] _-C alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -CI, -Br, or -I;
  • any two of Y , Y 2 , Y 3 , Y 4 and Y 5 present on adjacent carbon atoms can constitute a methylenedioxy group;
  • each X is independently S; 0; or NR 3 ;
  • R x is -H; -N0 2 ; -CN; straight chained or branched C ⁇ -C alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; or C0 2 (CH 2 ) n V;
  • R 2 is -H; straight chained or branched C ] _-C 7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C 3 -C 10 cycloalkyl-C 1 -C 10 -alkyl, C 3 -C 10 cycloalkyl-Cx-Cx Q -monofluoroalkyl or C 3 -C 10 cycloalkyl-C 1 - C 10 -polyfluoroalkyl; -CN; -CH 2 XR 3 , -CH 2 X (CH 2 ) p NHR 3 , -(CH 2 ) n
  • each R 3 is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • each R is independently -H; -F; straight chained or branched C ] _-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -OR 3 ; or -CN(R 3 ) 2 ;
  • B is N or CY 4 ;
  • each D is independently C(R 3 ) 2 ; 0; S; NR 3 ; CO; or CS; wherein each ⁇ is independently aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C ⁇ C- y alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or
  • V is C(R 5 ) 2 ; CR 5 R 6 ; NR 5 or NR 6 ;
  • W is CR 5 ; CR 6 or N;
  • Z is S; 0; C(R 3 ) 2 ; or NR 3 ;
  • each R 5 is -H; -N0 ; -N 3 ; -CN; straight chained or branched C x -C ⁇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ; -XC0R 8 ; or aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ;
  • each R 6 is independently -H; straight chained or branched C x -C 7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -C0R 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ;
  • R 7 is -H; aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; -XCOR 8 ; straight chained or branched C ] _-C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, or aminoalkyl; straight chained or branched C 2 -C alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 8 is -H; straight chained or branched C ] _-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) )
  • b is 1 or 2;
  • d is an integer from 0 to 2 inclusive;
  • each m is independently an integer from 0 to 3 inclusive;
  • n is independently an integer from 0 to 5 constitu ive ;
  • each p is independently an integer from 1 to 7 inclusive;
  • q is an integer from 1 to 3 inclusive
  • t is an integer from 2 to 6 ' inclusive;
  • each of Y , Y 2 , Y 3 , Y and Y 5 is independently -H; straight chained or branched C ⁇ ⁇ -C-y alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I;
  • any two of Y ⁇ r Y 2 , Y 3 , Y 4 and Y 5 present on adjacent carbon atoms can constitute a methylenedioxy group;
  • each X is independently S; 0; or NR 3 ; wherein R- L is -H; -N0 2 ; -CN; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; -C0N(R 3 ) 2 ; or C0 2 (CH 2 ) n V;
  • R 2 is -H; straight chained or branched C ⁇ -C- 7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C 3 -C 10 cycloalkyl-C 1 -C 10 -alkyl, C 3 -C 10 cycloalkyl-C 1 -C 10 -monofluoroalkyl or C 3 -C 10 cycloalkyl-C ] ⁇ - C 10 -polyfluoroalkyl; -CN; -CH 2 XR 3 , -CH 2 X (CH 2 ) p NHR 3 , -(CH 2 ) n
  • each R 3 is independently -H; straight chained or branched C -C ⁇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • each R is independently -H; -F; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -OR 3 ; or -CN(R 3 ) 2 ;
  • B is N or CY 4 ;
  • each D is independently C(R 3 ) 2 ; 0; S; NR 3 ; CO; or CS; wherein each U is independently aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C; L -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycl
  • V is C(R 5 ) 2 ; CR 5 R 6 ; NR 5 or NR 6 ;
  • W is CR 5 ; CR 5 or N;
  • Z is S; 0; C(R 3 ) 2 ; or NR 3 ;
  • each R 5 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C ⁇ ⁇ -C-y alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p 0R 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ; -XC0R 8 ; or aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3
  • each R 6 is independently -H; straight chained or branched C 1 -C 7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ;
  • R 7 is -H; aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; C0R 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -0R 3 ; -SR 3 ; (CH 2 ) q 0R 3 ; (CH 2 ) q SR 3 ; -XC0R 8 ; straight chained or branched C ⁇ C ⁇ y alkyl, monofluoroalkyl, polyfluoroalkyl, or aminoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 8 is -H; straight chained or branched Ci-C-y alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -C0N(R 3 ) 2 ; aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; C0R 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 )
  • b is 1 or 2;
  • d is an integer from 0 to 2 inclusive;
  • each m is independently an integer from 0 to 3 inclusive;
  • n is independently an integer from 0 to 5 inclusive ;
  • each p is independently an integer from 1 to 7 inclusive;
  • q is an integer from 1 to 3 inclusive
  • t is an integer from 2 to 6 inclusive
  • the present invention provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a compound of the aforementioned formula in an amount effective to treat the subject's depression and/or anxiety.
  • This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amounr. of a compound effective to decrease the consumption of food by the subject wherein the compound is selected from the group consisting of:
  • This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject.
  • This invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
  • This invention further provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier.
  • This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
  • This invention provides a compound having the structure
  • each of Y x , Y 2 , Y 3 , Y 4 and Y 5 is independently -H; straight chained or branched C ⁇ C- alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 3 , -OCOR 3 , -C0R 3 , -CON(R 3 ) 2 , or -COOR 3 ; or any two of Y x , Y 2 ,
  • Y 3 , Y 4 and Y 5 present on adjacent carbon atoms can constitute a methylenedioxy group
  • each X is independently S; 0; or NR 3 ;
  • R x is -H; -N0 2 ; -CN; straight chained or branched Ci-C- alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p 0R 3 ; -COR 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; or -C0 2 (CH 2 ) n V;
  • R 2 is -H; straight chained or branched C 1 -C 7 alkyl, hydroxyalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C 3 -C 10 cycloalkyl-C 1 -C 10 -alkyl, C 3 -C 10 cycloalkyl-C 1 -C 10 -monofluoroalkyl or C 3 -C 10 cycloalkyl-C L - C 10 -polyfluoroalkyl; -CN; -CH 2 XR 3 , -CH 2 X (CH 2 ) p NHR 3 , -(CH 2 ) n NHR 3 , -(
  • each R 3 is independently -H; straight chained or branched C j ⁇ -C- alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • dashed line represents a single bond or a double bond
  • each R is independently -H; -F; straight chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -0R 3 ; or -CON(R 3 ) 2 ;
  • each V is independently aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C- L -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • each R 5 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C ⁇ C- alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p 0R 3 ; -COR 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; CI; Br; I; C0R 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ;
  • R 6 is -H; straight chained or branched C x -C ⁇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ;
  • -CON(R 3 ) 2 aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; C0R 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q 0R 3 ; (CH 2 ) q SR 3 ; straight chained or branched C ⁇ C-y alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 7 is H; F; CI; Br; I; -N0 2 ; -N 3 ; -CN; straight chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p 0R 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ;
  • R 8 is independently straight chained or branched C- L -C- 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • Z is naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, phthalazinyl, quinoxalinyl, indolyl, benzo [b] furanyl, or benzo [b] thiophenyl; wherein the naphthyl, quinolinyl, isoquinolinyl, quinazolinyl, phthalazinyl, quinoxalinyl, indolyl, benzo [b] furanyl, or benzo [b] thiophenyl may be substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -0R 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C 1 -
  • n is independently an integer from 0 to 5 inclusive;
  • each p is independently an integer from 1 to 7 inclusive; wherein q is an integer from 1 to 3 inclusive;
  • r is an integer from 0 to 3 inclusive;
  • t is an integer from 2 to 6 inclusive
  • the compounds of this invention comprise the (+) enantiomer. In another embodiment, the compounds comprise the (-) enantiomer.
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound has the structure:
  • the compound has the structure
  • the compound has the structure:
  • A is
  • the compound has the structure :
  • the compound has the structure:
  • the compound has the structure
  • the compound has the structure :
  • the compound has the structure :
  • the compound has the structure
  • the compound has the structure :
  • the compound has the structure
  • A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • the compound has the structure
  • the compound has the structure:
  • the compound has the structure :
  • the compound has the structure:
  • A is
  • the compound has the structure
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is ( - ) -1, 2 , 3 , 6-tetra-hydro-l- ⁇ n- [4- (3 , -acet-amido) -phenyl- piperidin-1-yl] ropyl ⁇ carboxamido-4-methoxymethyl-6- (3,4- difluoro-phenyl) -2-oxopyrimidine-5-carboxylic acid methyl ester.
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • the compound has the structure
  • each R is independently -H; -F; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or j polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -SR 3 ; -C0 2 R 3 ; or
  • each R x is independently -H; straight cha'ined or branched C--C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ;
  • each R 2 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C j ⁇ -C-y alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ; or aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 )
  • each R 3 is independently -H; straight chained or branched C x -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • M is aryl or heteroaryl, optionally substituted with one or more F; CI; Br; I; C0R 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C 1 -C alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • X is (CH 2 ) n , O, S or NR 3 ;
  • aryl or heteroaryl optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C;L-C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl;
  • n is an integer from 0 to 6 inclusive
  • p is an integer from 1 to 4 inclusive
  • q is an integer from 1 to 3 inclusive
  • the compounds of this invention comprise the (+) enantiomer. In another embodiment, the compounds comprise the (-) enantiomer.
  • the compound has the structure:
  • W is phenyl optionally substituted with one or more F; Cl; Br; I; C0R 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; or (CH 2 ) q SR 3 .
  • the compound has the structure
  • the compound has the structure
  • each R is independently -H; -F; straight chained or branched C 1 -C alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -OR 3 ; or -CON(R 3 ) 2 ;
  • each R x is independently -H; F; Cl; Br; I; -N0 2 ; -N 3 ; -CN; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN
  • each R 3 is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 5 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C ] _-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl ; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -C0R 3 ; -C0 2 R 3 ; -C0N(R 3 ) 2 ; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; Cl; Br; I; C0R 3 ; C0 2 R 3 ; -C0N(R 3 ) 2 ; CN; -N
  • V is H; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ;
  • (CH 2 ) q SR 3 straight chained or branched C- L -C-y alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • aryl or heteroaryl optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C x -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl;
  • each m is independently an integer from 0 to 3 inclusive;
  • n is an integer from 0 to 2 inclusive;
  • p is an integer from 1 to 7 inclusive
  • q is an integer from 1 to 3 inclusive
  • t is an integer from 2 to 6 inclusive
  • the compounds of this invention comprise the (+) enantiomer. In another embodiment, the compounds comprise the (-) enantiomer.
  • the compound has the structure :
  • the compound has the structure
  • W is phenyl optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; or straight chained or branched C 1 -C 7 alkyl groups .
  • the compound has the structure
  • aryl includes phenyl and naphthyl and the term “heteroaryl” is used to include five and six membered unsaturated rings that may contain one or more heteroatoms such as oxygen, sulfur, and nitrogen.
  • heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.
  • heteroaryl is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen.
  • heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo [b] furanyl, benzo [b] thiophenyl , indazolyl, benzimidazolyl , benzthiazolyl , purinyl, imidazo [2 , 1-jb] thiazolyl, quinolinyl, isoquinolinyl, quinolizinyl, and 2,1,3- benzothiazolyl .
  • the salts include but are not limited to the acids and bases listed herein.
  • the salts include, but are not limited to the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and boric acid.
  • the salts include, but are not limited to the following organic acids: acetic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, maleic acid, citric acid, methanesulfonic acid, benzoic acid, glycolic acid, lactic acid and mandelic acid.
  • the salts include, but are not limited to the inorganic base, ammonia.
  • the salts include, but are not limited to the following organic bases: methylamine, ethylamine, propylamine, dimethylamine, diethylamine, trimethylamine, triethylamine, ethylenediamine, hydroxyethyla ine, morpholine, piperazine and guanidine .
  • This invention further provides for the hydrates and polymorphs of all of the compounds described herein .
  • the present invention includes within its scope prodrugs of the compounds of the invention.
  • prodrugs will be functional derivatives of the compounds of the invention which are readily convertible in vivo into the required compound.
  • the term "administering" shall emcompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
  • the present invention further includes metabolites of the compounds of the present invention.
  • Metabolites include active species produced upon introduction of compounds of this invention into the biological milieu.
  • This invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
  • the amount of the compound is an amount from about 0.01 mg to about 800 mg .
  • the amount of the compound is an amount from about 0.01 mg to about 500 mg .
  • the amount of the compound is an amount from about 0.01 mg to about 250 mg .
  • the amount of the compound is an amount from about 0.1 mg to about 60 mg .
  • the amount of the co pound is an amount from about 1 mg to about 20 mg .
  • the carrier is a liquid and the composition is a solution.
  • the carrier is a solid and the composition is a tablet.
  • the carrier is a gel and the composition is a suppository.
  • This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier.
  • This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier.
  • the "pharmaceutically acceptable carrier” is any physiological carrier known to those of ordinary skill in the art useful in formulating pharmaceutical compositions .
  • the pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution.
  • the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet.
  • the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream.
  • the compound may be formulated as a part of a pharmaceutically acceptable transdermal patch.
  • a solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins .
  • Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
  • the active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators .
  • suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution) , alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration.
  • the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent .
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously.
  • the compounds may be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
  • Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
  • the compound can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
  • solutes or suspending agents for example, enough saline or glucose to make the solution isotonic
  • bile salts for example, enough saline or glucose to make the solution isotonic
  • acacia gelatin
  • sorbitan monoleate sorbitan monoleate
  • polysorbate 80 oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide
  • compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
  • forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
  • the present invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound effective to decrease the consumption of food by the subject wherein the compound has the structure:
  • each of Y X l Y 2 , Y 3 , Y 4 and Y 5 is independently -H; straight chained or branched C;-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 3 , -OCOR 3 , -COR 3 , -CON(R 3 ) 2 , or -COOR 3 ; or any two of Y ⁇ r Y 2 , Y 3 , Y 4 and Y 5 present on adjacent carbon atoms can constitute a methylenedioxy group;
  • each X is independently S; 0; or NR 3 ;
  • R x is -H; -N0 2 ; -CN; straight chained or branched Ci-C-; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; or C0 2 (CH 2 ) n V;
  • R 2 is -H; straight chained or branched C 1 -C 7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C 3 -C 10 cycloalkyl-C; L -C 10 -alkyl, C 3 -C 10 cycloalkyl-C; L -C 10 -monofluoroalkyl or C 3 -C 10 cycloalkyl-C ; - C 10 -polyfluoroalkyl; -CN; -CH 2 XR 3 , -CH 2 X (CH 2 ) p NHR 3 , -(CH 2 )
  • each R 3 is independently -H; straight chained or branched C ; -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • each R is independently -H; -F; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -0R 3 ; or -CN(R 3 ) 2 ;
  • B is N or CY ;
  • each D is independently C(R 3 ) 2 ; 0; S; NR 3 ; CO; or CS;
  • each ⁇ is independently aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q 0R 3 ; (CH 2 ) q SR 3 ; straight chained or branched C- L -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • V is C(R 5 ) 2 ; CR 5 R 6 ; NR 5 or NR 6 ;
  • Z is S; 0; C(R 3 ) 2 ; or NR 3 ;
  • each R 5 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C ⁇ C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -C0R 3 ; -C0 2 R 3 ; or -C0N(R 3 ) 2 ; -XC0R 8 ; or aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; Cl; Br; I; C0R 3 ; C0 2 R 3 ; -C0N(R 3 )
  • each R 6 is independently -H; straight chained or branched C j ⁇ -C-y alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ;
  • R is -H; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ;
  • R 8 is -H; straight chained or branched C x -C alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR
  • b is 1 or 2;
  • d is an integer from 0 to 2 inclusive;
  • each m is independently an integer from 0 to 3 inclusive;
  • n is independently an integer from 0 to 5 inclusive;
  • each p is independently an integer from 1 to 7 inclusive;
  • q is an integer from 1 to 3 inclusive
  • t is an integer from 2 to 6 inclusive
  • the compound has the structure
  • the compound has the structure
  • the compound has the structure
  • At least one R 5 group is an aryl or heteroaryl group optionally substituted with one or more F; Cl; Br; I; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -XCOR 8 ; or straight chained or branched C- L -C 7 alkyl.
  • A is :
  • the compound is selected from the group consisting of:
  • the compound has the structure
  • the compound has the structure
  • A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R 7 is phenyl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; -XCOR 3 ; or straight chained or branched C- L -C 7 alkyl.
  • the compound has the structure
  • the compound has the structure
  • the compound has the structure
  • A is
  • the compound is selected from the group consisting of
  • the compound has the structure
  • the compound has the structure
  • A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound has the structure
  • the compound has the structure
  • the compound has the structure
  • the compound has the structure
  • the compound has the structure
  • the compound has the structure
  • each of Y x , Y 2 , Y 3 ,. Y 4 and Y 5 is independently -H; straight chained or branched C J ⁇ -C- J alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I;
  • any two of Y x , Y 2 , Y 3 , Y 4 and Y 5 present on adjacent carbon atoms can constitute a methylenedioxy group;
  • each X is independently S; 0; or NR 3 ; wherein R x is -H; -N0 2 ; -CN; straight chained or branched Ci L -C- alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; ⁇ OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; -CON(R 3 ) 2 ; or C0 2 (CH 2 ) n V;
  • R 2 is -H; straight chained or branched C- L -C 7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or .alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C 3 -C 10 cycloalkyl-C 1 -C 10 -alkyl, C 3 -C 10 cycloalkyl-C 1 -C 10 -monofluoroalkyl or C 3 -C 10 cycloalkyl-Ci- C 10 -polyfluoroalkyl; -CN; -CH 2 XR 3 , -CH 2 X (CH 2 ) p NHR 3 , -(CH 2 ) n
  • each R 3 is independently -H; straight chained or branched C;-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • each R is independently -H; -F; straight chained or branched C; L -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; -N(R 3 ) 2 ; -N0 2 ; -CN; -C0 2 R 3 ; -OR 3 ; or -CN(R 3 ) 2 ;
  • B is N or CY ;
  • each D is independently C(R 3 ) 2 ; 0; S; NR 3 ; CO; or CS;
  • each U is independently aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -0R 3 ; -SR 3 ; (CH 2 ) q OR 3 ; (CH 2 ) q SR 3 ; straight chained or branched C; L -C 7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C 2 -C 7 alkenyl, C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • V is C(R 5 ) 2 ; CR 5 R 6 ; NR 5 or NR 6 ;
  • W is CR 5 ; CR 6 or N;
  • Z is S; 0; C(R 3 ) 2 ; or NR 3 ;
  • each R 5 is -H; -N0 2 ; -N 3 ; -CN; straight chained or branched C ⁇ C-y alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -0R 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ; -XCOR 8 ; or aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more F; Cl; Br; I; C0R 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN
  • each R 6 is independently -H; straight chained or branched C 1 -C 7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
  • R 7 is -H; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ;
  • R 8 is -H; straight chained or branched L -C-; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -C0 2 R 3 ; or -CON(R 3 ) 2 ; aryl or heteroaryl, optionally substituted with one or more F; Cl; Br; I; COR 3 ; C0 2 R 3 ; -CON(R 3 ) 2 ; CN; -N0 2 ; -N(R 3 ) 2 ; -OR 3 ; -SR 3 ; (CH 2 ) q OR
  • b is 1 or 2;
  • d is an integer from 0 to 2 inclusive;
  • each m is independently an integer from 0 to 3 inclusive;
  • n is independently an integer from 0 to 5 inclusive;
  • each p is independently an integer from 1 to 7 inclusive;
  • q is an integer from 1 to 3 inclusive
  • t is an integer from 2 to 6 inclusive
  • the present invention provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a compound of the aforementioned formula in an amount effective to treat the subject's depression and/or anxiety.
  • This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound effective to decrease the consumption of food by the subject wherein the compound is selected from the group consisting of:
  • This invention further provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the present invention effective to decrease the consumption of food by the subject.
  • This invention also provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the present invention effective to decrease the consumption of food by the subject.
  • the feeding disorder is bulimia, obesity or bulimia nervosa.
  • the subject is a vertebrate, a mammal , a human or a canine .
  • the compound is administered in combination with food.
  • a "therapeutically effective amount" is any amount of a compound which, when administered to a subject suffering from a disease against which the compounds are effective, causes reduction, remission, or regression of the disease.
  • Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.
  • compositions which need not be pharmaceutical as that term is understood in the art.
  • Such compositions comprise a compound in accordance with the subject invention in an amount effective to antagonize an MCHl receptor and a suitable carrier.
  • the invention provides a method of agonizing and/or antagonizing an MCHl receptor which comprises contacting the receptor, e.g. in vitro or in in vivo, with an amount of a compound of this invention effective to agonize and/or antagonize the receptor.
  • PYRIMIDINE To a stirring solution of 5- (benzyloxycarbonyl) -1, 6-dihydro-2- methoxy-4-ethyl-6- (3 , 4-difluorophenyl) pyrimidine (17.0 g, 44.0 mmol) and 4-dimethylaminopyridine (7.00 g, 57.3 mmol) in CH 2 C1 2 (200 mL) was added 4-nitrophenyl chloroformate as a powder (11.5 g, 57.1 mmol) at room temperature. The reaction mixture was stirred for 12 h and then the solvent was removed in vacuo .
  • the organic layer was dried over Na 2 S0 4 , filtered and solvent was removed in vacuo.
  • the resulting mixture of diastereomers was separated by column chromatography (petroleum ether/ether, 9/1 to 4/1) .
  • the first major product to elute was (+) -5- (benzyloxycarbonyl) -4-ethyl- 1, 6-dihydro-l- ⁇ N- [1- phenyl) -ethyl] ⁇ carboxamido-2- methoxy-6- (3, -difluorophenyl) pyrimidine .
  • 5-METHYLBENZFUROXAN 4-Methyl-2-nitroaniline (100 g, 0.650 mol) was suspended in saturated methanolic sodium hydroxide solution (1.50 L) . This suspension was cooled (5 °C) and aqueous sodium hypochlorite until the red color disappeared. The resulting fluffy yellow precipitate was filtered, washed with cold water and recrystallized from ethanol, giving 5-methylbenzfuroxan (88.2 g, 89 % yield) as a pale yellow solid: H NMR d 2.39 (s, 3 H) , 6.90-7.40 (br m. 3 H) .
  • 5-METHYLBENZOFURAZAN To 5-Methylbenzfuroxan (88.2 g, 0.590 mol) in refluxing EtOH (75 mL) was added dropwise P(OEt) 3 (150 mL) . Heating was continued at reflux temperature for 1 h. The solvent was removed in vacuo and the residue was shaken with water (200 mL) and allowed to stand overnight at (0-5 °C) . The resulting brown solid was filtered, washed with water.
  • 5-DIBROMOMETHYLBENZOFURAZAN An anhydrous solution of 5-methylbenzofurazan (70.0 g, 0.520 mol), N-bromosuccinamide (325 g) , and benzoyl peroxide (0.50 g) in carbon tetrachloride (1.5 L) was heated at reflux temperature with stirring for 30 h. The reaction mixture was washed with water (2 X 500 mL) , dried (NaS0 4 ) , and the solvent was removed in vacuo .
  • 6- (3, 4-DIFLUOROPHENYL) -1,2,3, 6-TETRAHYDRO-2-OXO-5-METHOXY CARBON-YL-4-METHYL-l- ( 4-NITROPHENOXY) CARBONYLPYRIMIDINE : Aqueous 6 N hydrochloric acid (10 mL) was added to a stirring solution of 6- (3, 4-difluorophenyl) -1, 6- dihydro- 2-methoxy-5-methoxycarbonyl- 4-methyl-1-
  • reaction mixture was cooled to -78 °C and tert- butyl 4-oxo-l-piperidinecarboxylate (40.0 mmol) in THF (40 mL) was added dropwise to the reaction mixture and stirred for 30 minutes.
  • Tf 2 NPh (15.0 g, 42.0 mmol) in THF (40 mL) was added dropwise to the reaction mixture and the mixture was stirred at 0 °C overnight.
  • the reaction mixture was concentrated in vacuo, re-dissolved in hexanes/EtOAc (9/1), passed through a plug of alumina and washed with hexanes/EtOAc (9/1) .
  • TERT-BUTYL 4-[3-(ACETYLAMINO)PHENYL]-l,2,3, 6- TETRAHYDRO-1- PYRIDINECARBOXYLATE A mixture of saturated of aqueous Na 2 C0 3 solution (25 mL) , tert-butyl 4- ⁇ [ (trifluoromethyl) sulfonyl] oxy ⁇ - 1,2,3,6- tetrahydro-1-pyridine-carboxylate (20 mmol) , 3-acet- amidophenylboronic acid (30 mmol) and tetrakis- triphenylphosphine palladium (0) (1.15 g) and dimethoxyethane (40 mL) was heated at reflux temperature overnight.
  • PIPERIDINECARBOXYLATE A mixture tert-butyl 4- [3- (acetylamino) phenyl] -1,2,3, 6-tetra-hydro-l- pyridinecarboxylate (710 mg) and 5% Pd/C (100 mg) in EtOH (10 mL) was hydrogenated (balloon technique) at room temperature overnight. The reaction mixture was passed through a pad of Celite 545 and the pad of Celite was washed with ethanol. The combined ethanol extracts were concentrated and chromatograghed, giving the desired product (660 mg) . : H NMR ⁇ 7.80 (s, 1 H) , 7.41-7.20 (m, 3
  • 1-BENZYL-4-METHYL-4-PHENYLPIPERIDINE l-Benzyl-4-methyl- piperidin-4-ol (4.81 g, 23.4 mmol) was added to a suspension of A1C1 3 (15.62 g, 117 mmol) in benzene (100 mL) at room temperature under argon. The mixture was stirred at reflux for 24 hours, then cooled and poured cautiously into ice water (100 g of ice, 50 mL of water) . The aqueous phase was adjusted to pH 11-12 by addition of 6 N aqueous NaOH at 0 °C, and extracted with EtOAc (3 x 100 mL) .
  • the aqueous phase was adjusted to pH 11 by addition of 1 N aqueous NaOH.
  • the organic phase was separated, dried over magnesium sulfate and concentrated.
  • the residual oil was purified by flash chromatography (CHCl 3 /MeOH/2 N NH 3 in MeOH 100/4/0 to 100/20/10), giving l-benzyl-4- methyl-4- phenylpiperidine (1.20 g) and 1.10 g (51%, 82% based on consumed starting material) of 4-methyl-4-phenylpiperidine :
  • the solvent was evaporated from the filtrate and residue was dried under vacuum for 4 h.
  • the crude product was dissolved in 50 mL of chloroform, stirred for 1 h, and filtered. The white solid was washed with additional chloroform (20 mL) , the solvent was evaporated from the combined filtrates to leave the crude product as an oil .
  • the oil was purified by column chromatography (dichloromethane / methanol / 2 M ammonia in methanol, 10/3/1), giving the desired product (2.70 g, 93%).
  • TETRAHYDRO-1-PYRIDINECARBOXYLATE n-Butyl lithium (17.6 mL, 44.2 mmol, 2.5 M in hexanes) was added to a solution of diisopropyl amine (96.2 mL,
  • 1,2, 3, 6-TETRAHYDRO-4- (3-NITROPHENYL) PYRIDINE Into a stirred solution of 5.00 -g (16.0 mmol) of tert-butyl 1,2,3, 6-tetrahydro-4- (3-nitrophenyl) pyridine-1- carboxylate in 100 ml of 1,4-dioxane at 0°C was bubbled HCl gas for 10 minutes. The reaction mixture was allowed to warm to room temperature and the bubbling of the HCl gas was continued for an additional 1 hour. The solvent was removed in vacuo, the residue was dissolved in 50 mL of water and was neutralized by the addition of KOH pellets.
  • TERT-BUTYL 3- (4- (3-NITROPHENYL) -3 , 6-DIHYDRO-l (2H) - PYRIDINYL) PROPYLCARBAMATE : A mixture of 2.80 g (14.0 mmol) of 1, 2, 3, 6-tetrahydro-4- (3-nitrophenyl) pyridine, 3.60 g (15.0 mmol) of tert-butyl N-(3- bromopropyl) carbamate, 11.6 g (84.0 mmol) of K 2 C0 3 , 14.6 mL (84.0 mmol) of diisopropylethylamine and 0.78 g (2.00 mmol) of tetrabutylammonium iodide in 250 mL of 1,4- dioxane was heated at reflux temperature for 14 hours.
  • TETRAHYDRO-5-PYRIMIDINECARBOXYLATE A mixture of 3.02 g (6.33 mmol) 5-methyl 1- ( 4-nitrophenyl) (6S)-6-(3,4- difluorophenyl) -4- (methoxymethyl) -2-oxo-3, 6-dihydro- 1, 5 ( 2H) -pyrimidinedicarboxylate, 1.50 g (5.80 mmol) of 3- (4- (3-nitrophenyl) -3, 6-dihydro-l (2H) -pyridinyl) -1- propanamine, 7.94 g (75.5 mmol) of K 2 C0 3 and 1.00 L of methanol in 200 mL dichloromethane (under argon) was stirred at room temperature for 1 hour.
  • the reaction mixture was filtered and concentrated in vacuo .
  • the residue was dissolved in 100 L of ethyl acetate and washed 3 X 50 mL of 5% aqueous NaOH solution, the organic layer was dried (MgS0 4 ) and concentrated in vacuo .
  • the residue was dissolved in 100 mL of anhydrous ethanol containing 0.50 g 10% Pd/C and the reaction mixture was stirred under a hydrogen balloon for 24 hours.
  • the reaction mixture was passed through a column of Celite 545 filtering agent, washed with ethanol, the filtrate was dried (MgS0 4 ) and concentrated in vacuo .
  • reaction mixture was flushed with Argon three times, then the reaction mixture was heated to 100 °C for 3 hrs. After cooling to room 'temperature, the reaction mixture was diluted with methylene chloride (30 mL) and water (30 mL) and the organic layer was separated. The aqueous layer was extracted with methylene chloride (3x20 mL) and the combined organic extracts were washed with sat NH 4 C1 (20 mL) and brine (20 mL) , dried over MgS0 4 and concentrated under reduced pressure.
  • 4- (4-Nitrophenyl) -1,2,3, 6 tetrahydropyridine was prepared by a similar procedure to that used for the preparation of 2-methyl-W- [3- ( 4- piperidinyl) phenyl] propanamide using HCl gas and tert- Butyl 4- (4-Nitrophenyl) -3, 6-dihydro-l ⁇ 2H) - pyridinecarboxylate (130 mg) in dioxane (5.0 mL) at room temperature. The reaction mixture was concentrated in va cuo to give the crude product (69.8 mg) that used in the next reaction without further purification.
  • BENZYL 6- (3 , 4-DIFLUOROPHENYL) -4-ETHYL-2-METHOXY-1 , 6- DIHYDRO-5-PYRIMIDINECARBOXYLATE.
  • (+) -BENZYL 6- (3, 4-DIFLUOROPHENYL) -4-ETHYL-2-METHOXY-1, 6- DIHYDRO-5-PYRIMIDINECARBOXYLATE.
  • (+) -benzyl 6- (3, 4-difluorophenyl) -4-ethyl-2-methoxy- 1- ( ⁇ [ (li?) -1-phenylethyl] amino ⁇ carbonyl) -1, 6-dihydro-5- pyrimidinecarboxylate (17.1 mmol, 9.35 g) in CH 2 C1 2 was added 1, 8-diazabicyclo [5, 4 , 0] -undec-7-ene (17.1 mmol, 2.56 mL) and stirring was continued for 16 h at room temperature.
  • (+) -benzyl 6- (3, 4- difluorophenyl) -4-ethyl-2-methoxy-l, 6-dihydro-5- pyrimidinecarboxylate 6. 4 g, 16.0 mmol
  • pyridine 1.5 mL
  • 4-nitrophenyl chloroformate (3.41 g, 19.2 mmol) at room temperature.
  • PYRIMIDINEDICARBOXYLATE Into a well-stirred solution of 6- (3, 4-Difluorophenyl) -1, 6-dihydro-2-methoxy-5- methoxycarbonyl-4-methyl-l- [ (4- nitrophenyloxy) carbonyl] pyrimidine (1.5 mmol, 0.66 g) in 5 L of chloroform was added a solution of bromine (1.5 mmol, 0.09 mL) in 3 mL of chloroform at 0 °C and the solution was allowed to attain room temperature over 1.5 h. The solvent was removed in vacuo and the residue was again dissolved in CHC1 3 (20 mL) and washed with brine.
  • TERT-BUTYL N-(4-[ ( 1-NAPHTHYLCARBONYL) AMINO] - CYCLOHEXYLMETHYL) -CARBAMATE A mixture of 1-naphthoic acid (1.00 mmol, 0.172 g) , DMAP (2.00 mmol, 0.250 g) and ECD (0.383 g, 2.00 mmol) in dry dichloromethane (20 mL) was stirred at room temperature for 0.5 h followed by the addition of tert-butyl (4-amino) cyclohexyl) ethylcarbamate amine (1.09 mmol, 0.250 g) .
  • 4-ACETYL-l- (3-AMINOPROPYL) -4-PHENYLPIPERIDINE A solution of 4-Acetyl-4-phenylpiperidine (7, 1.53 g, 7.50 mmol), 3-bromo-propylamine hydrobromide (1.64 g, 7.50 mmol) and potassium carbonate (1.24 g, 9.00 mmol) was stirred in refluxing 1,4-dioxane (50 mL) for 12 h. After removal of dioxane, water (50 mL) was added and the pH was adjusted to 11-12 by addition of 1 N aqueous NaOH. The mixture was extracted with CH 2 C1 2 (100 L + 3 x 50 mL) .
  • the reaction mixture was stirred at room temperature for 12 h.
  • the reaction mixture was quenched with aqueous 6 N HCl .
  • the reaction mixture was concentrated to a small volume, partitioned between dichloromethane and water (100 mL each) , the mixture was adjusted to pH 8 by addition of Na 2 C0 3 , the layers were separated, and the aqueous layer was extracted with dichloromethane (3 x 30 mL) .
  • the combined organic extracts were dried (Na 2 S0 4 ) and the product was chromatographed, giving the desired product.
  • the HCl salt was prepared by the addition of 1 N HCl in ether to a solution of the product in CH 2 C1 2 .
  • Example 8 6- (BENZOFURAZAN-5-YL) -1,2,3, 6-TETRAHYDRO-5-METHOXYCARBONY L-4- METHYL-2-OXO-l- ⁇ N- [3- (4-PHENYLPIPERIDIN-l-YL) PROPYL] ⁇ CARBOXAMIDO-PYRIMIDINE: A solution of 6- (benzofurazan- 5-yl) -1, 6-dihydro-2- methoxy-5-methoxycarbonyl- 4 -methyl-1- ⁇ N- [3- (4-phenylpiperidin-l- yl) propyl] ⁇ carboxamidopyrimidine in MeOH was treated with 6 N HCl at 0 °C .
  • Example 9 4- (3-METHOXY) -PHENYL PIPERIDINE: HCl salt; mp 150-154 °C; l R NMR52.04 (s, br, 2H) , 2.25 (s, br, 2H) , 2.80 (s, br, IH) , 3.09 (s, br, 2H) , 3.66 (s, 2H) , 3.78 (s, 3H) , 6.79 (s, br, 3H) , 7.23 (s, IH) , 9.41 (s, br, IH) .
  • the compound of Example 10 may also be prepared via hydrogenation of the compoun of example 2 (H 2 balloon method, methanol, Pd/C, overnight) .
  • a synthetic path analogous to the latter route (Scheme 11) was used in the preparation of the tritiated analog, which in turn, was used as a radioligand in the MCH pharmacological assays.
  • 3- (4-PHENYLPIPERIDIN-l-YL) PROPYLAMINE A solution of BH 3 in THF (1.0 M, 83.0 mL, 83.0 mmol, 3.5 eq) was added to a stirring solution of 3- (4-phenylpiperidin-l-yl) - propionitrile (5.10 g, 24.0 mmol) in anhydrous THF (20 mL) under argon at room temperature. The mixture was heated at reflux temperature for 4.5 hours and then cooled to room temperature. Aqueous 6 N HCl (130 mL) was added and stirring was continued for 2 hours at 50-70 °C .
  • the mixture was basified to pH 9 by addition of aqueous 6 N NaOH and extracted with EtOAc (100 mL) and CH 2 C1 2 (3 x 100 L) .
  • the combined organic extracts were dried over magnesium sulfate and concentrated.
  • the residue was dissolved in CH 2 C1 2 (20 mL) and treated with HCl in ether (1.0 M, 50 mL) .
  • the solvents were removed, ether (250 mL) was added, the mixture was filtered, and the filter cake was washed with ether. Water ⁇ 60 mL) was added to the resulting white solid, 1 N NaOH was added until pH 10-11 was reached, and then the aqueous phase was extracted with CH 2 C1 2 (3 X 50 mL) .
  • the combined extracts were dried over magnesium sulfate and the solvents were evaporated, giving the desired product (4.50 g, 87%) .
  • 6-(3,4-DIFLOUROPHENYL) -1,2,3, 6-TETRAHYDRO-5-METHOXYCARBON YL-4- METHYL-2-OXO-l- ⁇ N-[3- (4-PHENYLPIPERIDIN-l-YL) PROPYL] ⁇ CARBOXAMIDO-PYRIMIDINE: A solution of 6- (3, 4- difluorophenyl) -1, 6-dihydro- 2-methoxy-5-methoxy carbonyl-4-methyl-l- ⁇ N- [3- (4-phenyl-piperidin- 1-yl) propyl] ⁇ carboxamidopyrimidine (100 mg, 0.185 mmol, mp 43-45 °C) in MeOH (5 mL) was treated with aqueous 6 N HCl (1.5 mL) at 0 °C .
  • HYDROBROMIDE A solution. of 2 , 4 ' -dipyridyl (25.0 g, 160 mmol) and 3-bromopropyl-amine hydrobromide (35.0 g, 160 mmol) in DMF (60 mL) was heated at 90-95 °C for 10 h.
  • 3-AMINOPROPYL-4- (2-PYRIDYL) PIPERIDINE A suspension of 3- (3 ' , 6 ' -dihydro-2 ' -H- [2, 4 ' ' ] bipyridinyl-1 ' -yl) -propylamin e (3.48 g crude, 15.9 mmol) and Pearlman's catalyst (1.0 g) in MeOH (40 mL) was hydrogenated under 120 psi for 10 h, after which the reaction mixture was filtered through a pad of Celite and the solvent was removed.
  • the HCl salt was prepared by treatment of a solution of the free base in ether with 1 N HCl in ether.
  • the white powder was dried under reduced pressure: 1 H NMR ⁇ 2.05-2.20 (m, 4H) , 2.77-2.88 (m, 2H) , 3.00-3.20 ( , 4H) , 3.35-3.47 (m, 2H) , 3.47 (s, 3H) , 3.64-3.70 (m, 2H) , 3.71 (s, 3H) , 4.05 (br t, IH) , 4.67 (s, 2H) , 6.59 (s, IH) , 7.05-7.20 (m, 3H) , 7.79 (t, IH) , 8.00 (d, IH) , 8.43 (dt, IH) , 8.96 (br t, IH, NH) , 12.4 (br s, IH) . m.p. 188-191
  • PROPYLAMINE N- ( tert-utoxycarbonyl) -3-bromopropylamine (0.772 g, 3.27 mmol) and potassium carbonate (0.904 g, 6.54 mmol) were added to a stirring solution of the amine (0.566 g, 3.27 mmol) in dioxane ( 20 mL) and the reaction mixture was heated at reflux temperature for 24 h. The reaction mixture was cooled to room temperature, concentrated and partitioned between chloroform (40 mL) and water (5 mL) .
  • Trifluoroacetic acid (1 ml) was added to 1-tert- butoxycarbonyl-3- (4-spiro [isobenzo-furan-1 (3H) , 4 ' - piperidine] ) propylamine ( 0.180 g, 0.52 mmol) in dichloromethane (5 ml) and the resulting solution was stirred at room temperature for 1 hour. The solution was concentrated, neutralized with 10% KOH solution and extracted into dichloromethane (25 ml) . The organic layer was dried over sodium sulfate, filtered and concentrated, giving propylamine (0.156 g, 100%) which was used in the subsequent step without further purification .
  • reaction mixture was stirred for another 1 h after addition of 2 mL of 6N HCl.
  • the combined organic extracts were dried over sodium sulfate, filtered and concentrated.
  • Example 22 (+) -1,2, 3, 6-TETRAHYDRO-l- (N- [4- (BENZO-4' ,5' (H) FURAN) PIPER IDIN-1- YL] PROPYL ⁇ CARBOXAMIDO-4-ETHYL- 6- (3, 4- DIFLUOROPHENYL) -2-OXO- PYRIMIDINE-5-CARBOXAMIDE HYDROCHLORIDE: DMAP • ECD (0.250 mmol, 0.050 g) was added to a stirred mixture of (+) -1, 2, 3, 6-tetra-hydro-l- ⁇ N- [4- (benzo-4 ' , 5 ' (h) furan) piperidin-1-yl] propyl ⁇ carbox- amido-4-ethyl-6- (3, 4-difluorophenyl) -2-oxo-pyrimidine-5-c arboxyl-ic acid hydrochloride (0.100 mmol, 0.055 g
  • Example 23 (1) -1,2,3, 6-TETRAHYDRO-l- ⁇ N-[4- ( 3 , 4-DIHYDRO-2-OXOSPIRO- NAPHTHALENE-1 (2H) ) -PIPERIDINE-1-YL] PROPYL ⁇ CARBOXAMIDO-5- METHOXYCARBONYL-2- 0X0-6- ( 3 , 4-BENZOFURAZAN) -4- METHYLPYRIMIDINE HYDROCHLORIDE
  • Step B 1- (3-AMINOPROPYL) SPIRO [ISOCHROMAN-3 , 4 ' PIPERIDIN] -1-ONE : To 1- (3-tert-Butoxycarbonylaminopropyl) spiro [isochroman-3, 4 ' -piperidin] -1-one (0.144 g, 0.375 mmol) in 5 mL of dichloromethane, 1 mL of trifluoroacetic acid , was added and the solution stirred at room temperature for 1 h. The solution was concentrated, neutralized with 10 % KOH solution and extracted into 25 mL of dichloromethane. The organic layer was dried over sodium sulfate, filtered and concentrated, giving 0.110 g (100%) of the product which was used as such for the subsequent step.
  • reaction mixture was stirred for another 1 h after addition of 2 mL of 6N HCl.
  • the organic layer was dried over sodium sulfate, filtered and concentrated.
  • reaction mixture was stirred for another 1 h after addition of 2 mL of 6N HCl.
  • the organic layer was dried over sodium sulfate, filtered and concentrated.
  • Example 42 The product was obtained according to the method described for methyl (4S) -4- (3, 4-difluorophenyl) -3- ( ⁇ [3- (4- ⁇ 3- [ (3, 3-dimethylbutanoyl) amino] phenyl ⁇ -l- piperidinyl) propyl] mino ⁇ carbonyl) -6- (methoxymethyl ) -2- oxo-1, 2,3, 4-tetrahydro-5-pyrimidinecarboxylate .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés qui sont des antagonistes sélectifs pour les récepteurs (MCH1) d'hormone-1 concentrant la mélanine. L'invention concerne une composition pharmaceutique comprenant une quantité thérapeutiquement efficace du composé de l'invention et un support pharmaceutiquement acceptable. Cette invention concerne une composition pharmaceutique produite par combinaison d'une quantité thérapeutiquement efficace du composé de cette invention et d'un support pharmaceutiquement acceptable. Cette invention concerne encore un procédé permettant de produire une composition pharmaceutique comprenant la combinaison d'une quantité thérapeutiquement efficace du composé de l'invention et d'un support pharmaceutiquement acceptable. Cette invention concerne également un procédé permettant de modifier le comportement alimentaire d'un sujet, ce qui comprend l'administration au sujet d'une quantité efficace d'un composé de l'invention afin de diminuer la consommation d'aliments par le sujet. Cette invention concerne encore un procédé permettant de traiter un trouble de l'alimentation chez un sujet, ce qui comprend l'administration au sujet d'une quantité efficace d'un composé de l'invention afin de diminuer la consommation d'aliments par le sujet. Dans un mode de réalisation de l'invention, le procédé permet de traiter un trouble de l'alimentation qui est la boulimie, la boulimie nerveuse ou l'obésité.
EP01952440A 2000-07-05 2001-07-05 Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci Withdrawn EP1299362A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US610213 1990-11-06
US61021300A 2000-07-05 2000-07-05
PCT/US2001/021286 WO2002006245A1 (fr) 2000-07-05 2001-07-05 Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
EP1299362A1 true EP1299362A1 (fr) 2003-04-09
EP1299362A4 EP1299362A4 (fr) 2004-11-03

Family

ID=24444133

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01952440A Withdrawn EP1299362A4 (fr) 2000-07-05 2001-07-05 Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci

Country Status (5)

Country Link
EP (1) EP1299362A4 (fr)
JP (1) JP2004504303A (fr)
AU (1) AU783403B2 (fr)
CA (1) CA2384041A1 (fr)
WO (1) WO2002006245A1 (fr)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MXPA03000174A (es) 2000-07-06 2003-09-22 Neurogen Corp Ligandos de receptor de hormona concentradora de melanina.
US6858619B2 (en) 2001-05-04 2005-02-22 Amgen Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
JP2005515961A (ja) 2001-05-22 2005-06-02 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド：置換１−ベンジル−４−アリールピペラジン類似体
US7105544B2 (en) 2001-07-05 2006-09-12 Synaptic Pharmaceutical Corporation Substituted alkyl amido piperidines
US7199135B2 (en) 2001-07-05 2007-04-03 H. Lundbeck A/S Substituted alkyl amido piperidines
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US7160879B2 (en) 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
WO2003059289A2 (fr) 2002-01-10 2003-07-24 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003070244A1 (fr) * 2002-02-22 2003-08-28 Abbott Laboratories Antagoniste des effets d'une hormone de concentration de melanine et son utilisation
CN100374440C (zh) * 2002-06-27 2008-03-12 先灵公司 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
UA77814C2 (en) * 2002-07-03 2007-01-15 Lundbeck & Co As H Spirocyclic piperidines as antagonists of mch1 and use thereof
UA77536C2 (en) 2002-07-03 2006-12-15 Lundbeck & Co As H Secondary aminoaniline piperidines as mch1 antagonists and their use
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
DE10250743A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
ZA200503654B (en) 2002-11-06 2006-09-27 Amgen Inc Fused heterocyclic compounds
EP1567112B1 (fr) 2002-11-22 2008-10-15 Smithkline Beecham Corporation THIAZOLIDIN-4-ONES POUR INHIBER LES PROTÉINES hYAK3
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7727998B2 (en) 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
WO2004072018A1 (fr) * 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited Derive d'amine
JP4630555B2 (ja) * 2003-02-12 2011-02-09 武田薬品工業株式会社 アミン誘導体
TW200427679A (en) * 2003-02-28 2004-12-16 Schering Corp Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
WO2004080411A2 (fr) 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Antagonistes du recepteur de l'hormone concentrant la melanine et compositions et methodes associees
US20060194871A1 (en) * 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005007124A2 (fr) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Inhibiteurs dihydropyrimidine substituee de la fonction canaux calciques
WO2005028438A1 (fr) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
US20050176738A1 (en) * 2003-11-07 2005-08-11 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
CN1930126A (zh) 2004-03-05 2007-03-14 万有制药株式会社 吡啶酮衍生物
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
JP4975739B2 (ja) * 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
PE20070083A1 (es) 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
EP1916239A4 (fr) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Composé de pyridone
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
EP1944301A4 (fr) 2005-10-27 2012-01-04 Msd Kk Nouveau derive de benzoxathiine
CA2629018C (fr) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Derive spiro aza-substitue
ATE495157T1 (de) 2006-02-15 2011-01-15 Sanofi Aventis Neue aminoalkohol-substituierte aryldihydroisochinolinone, herstellungsverfahren und ihre verwendung als medikamente
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2698157B1 (fr) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2008038692A1 (fr) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. dÉrivÉ de diarylcÉtimine
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
PE20091309A1 (es) * 2007-12-21 2009-09-30 Astrazeneca Ab Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa
EP2264026A4 (fr) 2008-03-06 2012-03-28 Msd Kk Dérivé d'alkylaminopyridine
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010013595A1 (fr) 2008-07-30 2010-02-04 萬有製薬株式会社 Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons)–(6 chaînons)
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2010075069A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
EP2379547A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
TW201040154A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (fr) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Nouveaux derives d'azabenzimidazole cyclique utiles en tant qu'agents antidiabetiques
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CN104098562A (zh) * 2013-04-12 2014-10-15 苏州科捷生物医药有限公司 一种5,6-二氢吡啶[2,3-d]嘧啶-4,7(3H,8H)-二酮的合成方法
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
EP3924058B1 (fr) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
KR20220066252A (ko) 2019-07-11 2022-05-24 프락시스 프리시젼 메디신즈, 인크. T형 칼슘 채널 조절제의 제형 및 이의 사용 방법
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2021206286A1 (en) * 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2673381B2 (ja) * 1990-02-23 1997-11-05 持田製薬 株式会社 糖尿病前症治療剤および／または脂質低下剤
EE9700209A (et) * 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
CA2253862A1 (fr) * 1996-05-16 1997-11-20 Wai C. Wong Dihydropyrimidines et leurs emplois
US6245773B1 (en) * 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
DE69721541T2 (de) * 1996-07-23 2004-03-18 Neurogen Corp., Branford Einige amido-und amino-substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifischen liganden
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP2002514199A (ja) * 1997-02-04 2002-05-14 ブリストル−マイヤーズ スクイブ カンパニー Ｎｐｙ拮抗剤としてのジヒドロピリミドン誘導体
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
EP0921125B1 (fr) * 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag Derives de la 1,3,8-triazaspiro[4,5]decan-4-one
WO2000006565A1 (fr) * 1998-07-30 2000-02-10 Merck & Co., Inc. ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
US6632836B1 (en) * 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors

Also Published As

Publication number Publication date
AU783403B2 (en) 2005-10-20
CA2384041A1 (fr) 2002-01-24
EP1299362A4 (fr) 2004-11-03
JP2004504303A (ja) 2004-02-12
AU7319201A (en) 2002-01-30
WO2002006245A1 (fr) 2002-01-24

Similar Documents

Publication Publication Date Title
AU783403B2 (en) Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US6720324B2 (en) Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
AU727972B2 (en) Dihydropyrimidines and uses thereof
US6245773B1 (en) 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP1246847A2 (fr) Adn codant pour un recepteur humain de l'hormone de concentration de la melanine (mch1) et ses applications
US6248747B1 (en) 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP1318811B1 (fr) Modulateurs cyclopentyles de l'activite du recepteur de la chimiokine
EP1531816B1 (fr) Piperidines spirocycliques utilisees comme antagonistes des mch1 et utilisations associees
JP2003525928A (ja) 新規ｃｃｒ５モジュレーター：ベンズイミダゾール類またはベンズトリアゾール類
US7105544B2 (en) Substituted alkyl amido piperidines
JP4870163B2 (ja) Ｍｃｈ受容体アンタゴニストとしてのインダン誘導体
WO2004064774A2 (fr) Adn codant un recepteur d'hormone de concentration de la melanine (mch1) humain et utilisations correspondantes
US7473698B2 (en) Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof
US20030077701A1 (en) DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
AU2006200052A1 (en) Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
WO2000037026A1 (fr) Dihydropyrimidines et leurs utilisations
JP2006525274A (ja) 新規なピペリジン誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHIU, GEORGE

Inventor name: NAGARATHNAM, DHANAPALAN

Inventor name: NOBLE, STEWART

Inventor name: GLUCHOWSKI, CHARLES

Inventor name: DELEON, JOHN, E.

Inventor name: MARZABADI, MOHAMMAD, R.

Inventor name: WETZEL, JOHN

Inventor name: LAGU, BHARAT

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/24 B

Ipc: 7A 61P 25/22 B

Ipc: 7A 61P 3/04 B

Ipc: 7A 61K 31/427 B

Ipc: 7A 61K 31/4192 B

Ipc: 7A 61K 31/4188 B

Ipc: 7A 61K 31/165 B

Ipc: 7A 61K 31/505 B

Ipc: 7C 07D 491/04 B

Ipc: 7C 07D 239/22 B

Ipc: 7C 07D 249/18 B

Ipc: 7C 07D 471/10 B

Ipc: 7C 07D 211/52 B

Ipc: 7C 07D 471/04 B

Ipc: 7C 07D 295/06 B

Ipc: 7C 07D 417/06 B

Ipc: 7C 07C 233/79 B

Ipc: 7C 07D 401/14 B

Ipc: 7C 07D 413/14 B

Ipc: 7C 07D 211/58 B

Ipc: 7C 07D 491/10 B

Ipc: 7C 07D 401/12 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040921

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: H. LUNDBECK A/S

17Q First examination report despatched

Effective date: 20050822

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070403

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054550

Country of ref document: HK